Aducanumab has taken one of the most winding paths of any drug in recent history.
After going through initial clinical testing, Biogen pushed two doses of the drug into a pair of large, identically-designed studies meant to prove its merit in early Alzheimer’s patients. The studies, named ENGAGE and EMERGE, started a month apart in the late summer of 2015. Biogen amended the studies a few times over the following few years, but the first major, course-changing event for aducanumab didn’t come until March 2019.
